Canada markets open in 7 hours 28 minutes

Syros Pharmaceuticals, Inc. (0S9.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.8390-0.0256 (-2.96%)
As of 08:11AM CEST. Market open.
Full screen
Previous Close0.8646
Bid0.7984 x 0
Ask0.8020 x 0
Day's Range0.8390 - 0.8390
52 Week Range0.6436 - 4.6400
Avg. Volume83
Market Cap52.705M
Beta (5Y Monthly)2.12
PE Ratio (TTM)N/A
EPS (TTM)-1.4760
Earnings DateAug 03, 2022 - Aug 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.14
  • Zacks

    Biotech Stock Roundup: VRTX's Regulatory Update, TYME Gains on Acquisition & More

    Regulatory and other updates from Vertex (VRTX) and TYME are a few key highlights from the biotech sector during the past week.

  • Business Wire

    Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement

    CAMBRIDGE, Mass. & BEDMINSTER, N.J., July 05, 2022--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and TYME Technologies, Inc. (NASDAQ:TYME), today announced that the companies have entered into a definitive merger agreement pursuant to which Syros will acquire TYME, including its pipeline assets and net cash at closing which after accounting for wind-down and transaction expenses is currently estimated to be approximately $60

  • Business Wire

    Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., July 01, 2022--Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 48,400 shares of Syros common stock to two newly hired employees in connection with their commencement of employment with Syros. These RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).